Article

Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma?

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars-Sinai Women's Cancer Research Institute, Los Angeles, CA 90048, USA.
Gynecologic Oncology (Impact Factor: 3.69). 02/2011; 120(2):189-92. DOI: 10.1016/j.ygyno.2010.10.038
Source: PubMed

ABSTRACT Prior studies have shown that age ≥70 years is associated with more aggressive non-endometrioid histology and worse survival in endometrial cancer. The purpose of this study is to assess if age is an independent poor prognostic factor in endometrioid histologies.
Under an IRB-approved protocol, we identified patients with surgical stage I to II endometrioid endometrial adenocarcinoma from 1995 to 2008 at two institutions. Patients were divided into two groups based on age at diagnosis: Group A (age 50-69 years) and Group B (age≥70 years). All patients underwent hysterectomy, bilateral salpingoophorectomy, +/-pelvic/aortic lymphadenectomy and adjuvant therapy. Prognostic factors were evaluated by univariate and multivariate analyses.
We identified 338 patients with stage IA to IIB endometrioid endometrial adenocarcinoma. The median age in Group A was 59 years (range 50-69) and Group B was 75 years (range 70-92). Patients in Group B were more likely to have hypertension (51% vs. 68%, p=0.006) and coronary artery disease (9% vs. 18%, p=0.03). There were no differences in progression-free or disease-specific survival, however, Group B had a worse overall survival (OS) (50.1 vs. 62.6 months, p=0.03). On univariate analysis, age (p=0.04), grade (p=0.006), and coronary artery disease (p=0.01) were associated with worse OS. After adjusting for grade and coronary artery disease, age was no longer a significant variable for OS (p=0.17).
After adjusting for other poor prognostic factors, age ≥70 years alone may not be a significant variable affecting overall survival in patients with early stage endometrioid endometrial adenocarcinoma.

1 Follower
 · 
98 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reflecting the worldwide aging trend and close association of aging with cancer, geriatric oncology is now growing beyond its pioneer years. Nevertheless, geriatric oncology in the gynecologic field is in the beginning stage; indeed, there is no geriatric specialist who is trained in this particular field of gynecologic oncology. Therefore, we held the first workshop in geriatric gynecologic oncology. In this review, we summarize what we discussed at the workshop and provide evidence-based recommendations for the diagnosis and treatment of gynecologic cancer in elderly individuals.
    International Journal of Gynecological Cancer 11/2011; 22(1):161-9. DOI:10.1097/IGC.0b013e318234f8d5 · 1.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many studies have examined the impact of older age on tumor recurrence and survival after hysterectomy for patients with endometrioid carcinoma. However, there is paucity of data examining the prognostic significance of age in patients with Type II endometrial carcinoma. The study was conducted to determine the prognostic impact of age in this patient population. In this Institutional Review Board (IRB)-approved study, our prospectively-maintained database of 1305 patients with endometrial cancer was reviewed. Seventy-two consecutive patients with serous and clear carcinoma 2009 FIGO stages I-II were identified with at least one year follow-up after surgical staging. Patients with mixed histology and those who received preoperative therapy were excluded. All the patients underwent surgical staging from 1989 to 2009. Their medical records were reviewed. The study cohort was divided into two groups based on their age at hysterectomy (≤ 65 vs. >65). Patient's demographics, pathologic features and treatment-related factors were compared. The impact of age on recurrence-free survival (RFS), disease-specific survival (DSS) and overall survival (OS) were calculated. Following univariate analysis, multivariate modeling was done using step-wise Cox proportional hazards analysis to assess the impact of age on clinical outcomes after adjusting for various clinical variables. Median follow-up for the study cohort was 45 months (range 13-246). Fifty percent of patients received adjuvant platinum-based chemotherapy and/or adjuvant radiation treatment (RT). Thirty-five patients were older than 65 years (49%) and 37 were ≤ 65 (51%). There were no significant differences between the two groups in regard to race (African American vs Caucasian), FIGO stage, number of lymph nodes dissected, lymphovascular space involvement (LVSI), or adjuvant therapy received. There were more clear cell histology in the younger age group (p=0.035). Patients >65 years old developed more recurrences with a 5-year RFS of 59% compared to 84% for younger patients (p=0.036). The five-year DSS was not statistically different between the two groups (68% vs. 79%, respectively with p=0.313). 5-year OS was significantly shorter in the elderly patients (58% vs. 78% with p=0.014). On multivariate analysis, the presence of LVSI, not receiving RT and age >65 were independent predictors of worse RFS (p=<0.001, 0.005, and 0.040 respectively). In this study for surgically staged FIGO I-II patients with Type II endometrial carcinoma, age more than 65 years is a significant adverse prognostic factor for tumor recurrence.
    Gynecologic Oncology 04/2012; 126(1):16-9. DOI:10.1016/j.ygyno.2012.04.011 · 3.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To estimate the prognostic significance of lymph node ratio with respect to clinicopathologic characteristics in stage IIIC endometrial cancer patients. Using data from medical records and surgery notes, we identified all consecutive patients with stage IIIC endometrial cancer who received primary surgical treatment between 1993 and 2008. Lymph node ratio is the number of metastatic lymph nodes to the total number of removed lymph nodes. Survival analyses were performed using Kaplan-Meier and Cox proportional hazard methods. Two hundred sixteen patients with stage IIIC endometrial cancer were included in this multicenter study. Age, number of metastatic lymph nodes, lymph node ratio, grossly suspicious lymph nodes, histologic subtype, and cervical metastasis were associated with progression-free survival and overall survival, respectively. Patients with lymph node ratios 10% or less, more than 10-50%, and more than 50% had 5-year overall survival rates of 79.0%, 60.6%, and 35.8%, respectively (P<.001). In multivariable analysis, only lymph node ratio was associated with both progression-free survival and overall survival, respectively. Total number of removed lymph nodes and number of metastatic lymph nodes did not correlate with overall survival in the group with grossly suspicious lymph nodes, whereas lymph node ratio did. In the subgroup of 123 (56.9%) patients who had pelvic and aortic lymphadenectomies with a minimum of 10 lymph nodes removed, age and lymph node ratio were still associated with progression-free survival and overall survival, whereas total lymph nodes removed was not. Stratification based on lymph node ratio is useful when comprehensive lymphadenectomy is routinely performed and likely reflects metastatic nodal tumor burden. These data provide another prognostic variable in the heterogenic group of women with stage IIIC endometrial cancer. II.
    Obstetrics and Gynecology 06/2012; 119(6):1210-8. DOI:10.1097/AOG.0b013e318255060c · 4.37 Impact Factor